Jove
Visualize
Contact Us

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical <i>EGFR</i> Mutation: A Molecular Tumor Board Discussion.

JCO precision oncology·2026
Same author

Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline.

JCO oncology practice·2026
Same author

plasmaCHORD: A Machine Learning Approach to Distinguish Clonal Hematopoiesis-Derived Variants in Liquid Biopsies from Patients with Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

Cancer research communications·2026
Same author

Automated Extraction of Cancer Registry Data from Pathology Reports: Comparing LLM-Based and Ontology-Driven NLP Platforms.

medRxiv : the preprint server for health sciences·2026
Same author

Durable disease control in a radiation-induced high-grade glioma harboring <i>NF1</i> and <i>PTPN11</i> co-mutations.

Neuro-oncology advances·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

A Precision Oncology Platform to Support Genotype-Tailored Therapy Selection.

Taxiarchis Botsis1, Jonathan Spiker1, Kory Kreimeyer1

  • 1Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Studies in Health Technology and Informatics
|August 23, 2024
PubMed
Summary

Identifying patients for clinical trials is challenging due to data integration issues. Our precision oncology platform streamlines this process for genotype-matched therapies.

Keywords:
Decision SupportMolecular Tumor BoardPrecision Oncology

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 15, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Current clinical trial and targeted therapy enrollment processes struggle with integrating diverse molecular data.
  • Identifying genotype-matched patients is critical but hampered by existing methodologies.

Purpose of the Study:

  • To develop a streamlined precision oncology platform for identifying eligible patients for clinical trials and targeted therapies.
  • To assist molecular tumor boards and community oncologists in patient data review and treatment matching.

Main Methods:

  • Development of a novel precision oncology platform.
  • Integration of diverse molecular data sources.
  • Facilitation of patient phenotype review and knowledge evaluation.

Main Results:

  • The platform enables efficient identification of genotype-matched individuals.
  • It supports molecular tumor boards and community oncologists in decision-making.
  • Streamlined access to targeted therapies and clinical trials is facilitated.

Conclusions:

  • The developed precision oncology platform addresses the critical need for efficient patient identification.
  • It enhances the process of matching patients to genotype-matched therapies and clinical trials.
  • This tool improves precision medicine by simplifying complex data analysis for oncologists.